Henning T. Mouridsen

Q: What Schools Are Affiliated With Henning T. Mouridsen

Henning T. Mouridsen is affiliated with the following schools: Aarhus University, University of Southern Denmark, University of Copenhagen

Henning T. Mouridsen's AcademicInfluence.com Rankings

Medical

#2538

World Rank

#2966

Historical Rank

Oncology

#159

World Rank

#165

Historical Rank

medical Degrees

Henning T. Mouridsen

Philosophy

#7325

World Rank

#10519

Historical Rank

Logic

#4386

World Rank

#5669

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Henning T. Mouridsen's Degrees

PhD Medical Science University of Copenhagen
Doctorate Medicine University of Copenhagen

Why Is Henning T. Mouridsen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Henning T. Mouridsen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. (1997) (2459)
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. (2005) (1554)
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial (1999) (1459)
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. (2001) (1025)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. (2007) (890)
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women (1988) (842)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. (2003) (738)
Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. (1992) (600)
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. (1999) (512)
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (1995) (496)
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. (2009) (486)
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. (1993) (431)
Factors influencing the effect of age on prognosis in breast cancer: population based study (2000) (394)
Tamoxifen in advanced breast cancer. (1978) (328)
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. (2005) (310)
Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. (1994) (290)
Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients (2007) (285)
Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). (1992) (273)
Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol (2008) (250)
The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise (2008) (246)
BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES (1985) (228)
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. (1987) (226)
Depression as a prognostic factor for breast cancer mortality. (2003) (217)
Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study (2005) (210)
Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. (1994) (207)
Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. (1991) (180)
Prognostic effect of estrogen receptor status across age in primary breast cancer (2007) (170)
The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG) (2004) (170)
Oral clodronate in breast cancer patients with bone metastases: a randomized study (1999) (169)
Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. (1996) (165)
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. (2002) (165)
Should women be advised against pregnancy after breast-cancer treatment? (1997) (162)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. (2011) (161)
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. (2009) (161)
Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. (1987) (158)
Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. (2006) (152)
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. (2007) (146)
Adjuvant radiotherapy and risk of contralateral breast cancer. (1992) (145)
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. (2006) (139)
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. (2011) (136)
Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. (1987) (136)
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. (2008) (136)
Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. (1989) (135)
Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult (1994) (128)
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. (2007) (127)
Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. (1992) (124)
Patient's and doctor's delay in primary breast cancer. Prognostic implications. (1994) (121)
Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group (1984) (120)
Tissue inhibitor of metalloproteinases-1 in breast cancer. (2005) (119)
[Danish Breast Cancer Cooperative Group]. (2012) (110)
The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D (2008) (108)
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. (2012) (108)
Effect of breast‐conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma (2004) (108)
Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. (1988) (106)
Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. (2008) (106)
High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. (1991) (105)
Danish Breast Cancer Cooperative Group--DBCG. (1977) (102)
Anxiety and depression in breast cancer patients at low risk of recurrence compared with the general population: a valid comparison? (1999) (101)
Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group. (1993) (101)
Time since childbirth and prognosis in primary breast cancer: population based study (1997) (101)
Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. (1987) (99)
A Danish randomized trial comparing breast-preserving therapy with mastectomy in mammary carcinoma. Preliminary results. (1988) (96)
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. (1998) (96)
Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays (2006) (94)
Second cancer following cancer of the female breast in Denmark, 1943-80. (1985) (94)
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. (2011) (91)
Organisation of the Danish adjuvant trials in breast cancer. (1981) (90)
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. (1993) (90)
Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. (2008) (83)
TIMP-1 as a tumor marker in breast cancer – An update (2008) (83)
Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast Cancer * (2003) (82)
Primary Tumor Levels of Tissue Inhibitor of Metalloproteinases-1 Are Predictive of Resistance to Chemotherapy in Patients with Metastatic Breast Cancer (2006) (80)
Parity, age at first childbirth and the prognosis of primary breast cancer. (1998) (78)
Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer (2008) (76)
Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients. (1984) (76)
Prognostic factors in osteosarcomas. A regression analysis (1988) (75)
Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. (2009) (74)
Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. (1993) (74)
Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin (1999) (72)
Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. (1995) (71)
Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. (1988) (67)
Clinical and radiologic characteristics of bone metastases in breast cancer (1987) (67)
Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. (2007) (66)
Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. (1992) (65)
Danish Breast Cancer Cooperative Group – DBCG: History, organization, and status of scientific achievements at 30-year anniversary (2008) (64)
A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. (2009) (63)
Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women (2006) (62)
Metastatic pattern in recurrent breast cancer: Special reference to intrathoracic recurrences (1988) (62)
Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. (1993) (59)
Prognostic influence of pregnancy before, around, and after diagnosis of breast cancer. (2003) (59)
alpha-fetoprotein levels in maternal serum during pregnancy and maternal breast cancer incidence. (2000) (58)
Influence of tumor location on breast cancer prognosis (2003) (58)
Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). (2004) (58)
Treatment of advanced breast cancer with tamoxifen. (1984) (57)
Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. (2011) (57)
Current status of epirubicin (Farmorubicin) in the treatment of solid tumours. (1990) (56)
HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. (2010) (55)
Reproductive risk factors for breast cancer by receptor status, histology, laterality and location (1999) (54)
Towards discovery‐driven translational research in breast cancer (2004) (52)
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. (2006) (51)
Risk of late-stage breast cancer after a childbirth. (2001) (51)
Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. (1979) (51)
BRCA1 andBRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age (2001) (51)
The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. (1995) (51)
Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer (2011) (50)
Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study. (1983) (48)
Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. (2004) (48)
Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen (2005) (48)
Challenges in the endocrine management of breast cancer. (2003) (47)
Medullary carcinoma of the breast, proposal for a new simplified histopathological definition. Based on prognostic observations and observations on inter- and intraobserver variability of 11 histopathological characteristics in 131 breast carcinomas with medullary features. (1991) (47)
Pharmacokinetics of cyclophosphamide in renal failure. (2009) (46)
Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B. (1988) (46)
Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG Registry (2008) (45)
Do clinical databases render population-based cancer registers obsolete? The example of breast cancer in Denmark (2000) (45)
The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016 (2018) (45)
Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. (2017) (44)
Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research* (2003) (44)
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. (1997) (44)
The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. (2005) (43)
The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects. (2009) (43)
Flow cytometric DNA ploidy defines patients with poor prognosis in node‐negative breast cancer (2007) (43)
Steroid hormone receptors as prognostic indicators in primary breast cancer. (1986) (43)
The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. (2000) (42)
The biotransformation of cyclophosphamide in man: influence of prednisone. (2009) (42)
Plasma and Serum Levels of Tissue Inhibitor of Metalloproteinases-1 Are Associated with Prognosis in Node-negative Breast Cancer (2008) (42)
Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen. (1985) (40)
A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement (2004) (40)
Danish Breast Cancer Cooperative Group (DBCG). Structure and results of the organization. (1988) (39)
BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. (2009) (38)
Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer. (1977) (38)
Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. (1986) (37)
Endocrine therapy of advanced breast cancer. (1988) (36)
Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff (2007) (35)
Inter- and intraobserver variability in the histopathological diagnosis of medullary carcinoma of the breast, and its prognostic implications (1989) (35)
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. (1993) (34)
Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study. (2009) (34)
A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer (1983) (32)
Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment (2016) (32)
Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group (2000) (32)
Timing of surgery in relation to menstrual cycle does not predict the prognosis in primary breast cancer. Danish Breast Cancer Cooperative Group. (1994) (31)
A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. (1993) (30)
The role of aromatase inhibitors in the treatment of metastatic breast cancer. (2003) (29)
Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial. (1999) (29)
CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial. (1980) (29)
Impact of Axillary Dissection on Staging and Regional Control in Breast Tumors = 10 mm: The DBCG experience (2000) (29)
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer (2009) (28)
Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG (1999) (28)
Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer (2014) (28)
Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. (1984) (28)
Therapeutic effect of tamoxifen related to estrogen receptor level. (1980) (27)
Measurement of the Uncomplexed Fraction of Tissue Inhibitor of Metalloproteinases-1 in the Prognostic Evaluation of Primary Breast Cancer Patients* (2005) (27)
Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present status of Danish Breast Cancer Cooperative Group trials. (1986) (27)
Long-term results of breast conserving surgery vs . mastectomy for early stage invasive breast cancer : 20-year follow-up of the Danish randomized DBCG-82 TM protocol (2008) (27)
The Head to Head trial: Letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. (2006) (26)
Depression as prognostic factor in breast cancer (1998) (26)
Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study. (1990) (26)
New cytotoxic drugs in treatment of breast cancer. (1990) (26)
Adjuvant systemic therapy in breast cancer; a review. (1983) (26)
Predicting recurrence in patients with breast cancer from cumulative laboratory results: a new technique for the application of time series analysis. (1982) (24)
Reproductive history and stage of breast cancer. (1999) (24)
Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high‐risk, premenopausal breast cancer (2010) (24)
Letrozole in advanced breast cancer: the PO25 trial (2007) (24)
Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial (2006) (24)
Danish Breast Cancer Cooperative Group (2016) (24)
Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. (2005) (24)
Letrozole in advanced breast cancer: the PO25 trial (2007) (23)
Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. (2012) (23)
E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma. (1979) (23)
Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials. (1980) (22)
Endocrine management of advanced breast cancer. (1989) (22)
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. (1990) (22)
Medullary carcinoma of the breast, prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis. (1994) (21)
Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized study (1992) (21)
Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer (2010) (21)
VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group. (1987) (21)
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863). (2006) (21)
Endocrine treatment with anti-estrogen, anti-androgen or progestagen of advanced malignant melanoma: three consecutive phase II trials. (1985) (21)
Extended radical mastectomy versus simple mastectomy followed by radiotherapy in primary breast cancer. A fifty-year follow-up to the Copenhagen Breast Cancer randomised study (2008) (20)
Therapeutic effect of tamoxifen alone versus tamoxifen in combination wtih gestagen and oestrogen in advanced breast cancer. (1980) (20)
Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer (2004) (20)
The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study. (2009) (20)
Regional trends in breast cancer incidence and mortality in Denmark prior to mammographic screening. (1994) (19)
Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen. (1985) (18)
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer (2009) (18)
Marginal surgery and postoperative radiotherapy in soft tissue sarcomas. The Scandinavian Sarcoma Group experience. (1993) (18)
The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man. (1975) (18)
CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D (2010) (17)
Aromatase inhibitors in advanced breast cancer. (2004) (17)
Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status (2012) (17)
Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone. (1978) (17)
Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer; A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age (2000) (17)
Tamoxifen treatment of advanced endometrial carcinoma. A phase II study. (1983) (16)
Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II study. (1983) (16)
Quality control of end results in a Danish adjuvant breast cancer multi-center study. (1997) (16)
Antiestrogen treatment of postmenopausal women with primary high risk breast cancer (1983) (16)
A modified Nottingham prognostic index for breast cancer patients diagnosed in Denmark 1978-1994. (2001) (16)
Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. (1995) (16)
Turnover of human serum albumin before and after operations. (1967) (16)
Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women. (1980) (15)
Applicability of the Intratumor Aromatase Preclinical Model to Predict Clinical Trial Results With Endocrine Therapy (2003) (15)
Prognostic Influence of Age at Diagnosis in Premenopausal Breast Cancer Patients (2002) (15)
Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes (2004) (15)
Mitomycin C (MCC) in advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (1985) (15)
Accumulation of serum-albumin at the operative wound site as a cause of postoperative hypoalbuminaemia. (1966) (15)
Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer (2005) (14)
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer. (2005) (14)
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas (2004) (14)
Classical prognostic factors in node-negative breast cancer: the DBCG experience. (1992) (14)
Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration (2018) (14)
Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial. (2011) (13)
Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study. (1994) (13)
Clinical and Histopathological Prognostic Factors in Chondrosarcomas (1997) (13)
Lack of effect of gold therapy on abnormal IgG and IgM metabolism in rheumatoid arthritis. (1974) (13)
Vinorelbine as first-line or second-line therapy for advanced breast cancer: A Phase I-II trial by the Danish Breast Cancer Co-operative Group (2008) (13)
Systemic Therapy of Advanced Breast Cancer (2012) (13)
Adjuvant endocrine therapy of breast cancer--a controlled clinical trial of oestrogen and anti-oestrogen: preliminary results of the Copenhagen breast cancer trials. (1980) (13)
The retention of different plasma proteins in wound tissue. (1969) (13)
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: Indirect comparison of dose and schedule in DBCG trials 77, 82, and 89 (2008) (13)
A model for determining the effect of mammography service screening (2005) (13)
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients (2020) (12)
The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol. (2009) (12)
Danish Breast Cancer Cooperative Group. (1982) (11)
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1 (2011) (11)
N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group. (1982) (11)
Endometrial carcinoma and tamoxifen: clearing up a controversy. (1996) (11)
TOP2A aberrations as predictive and prognostic marker in high-risk breast cancer patients. A randomized DBCG Trial (DBCG89D). (2006) (11)
TOP2A , TIMP-1 and responsiveness to adjuvant anthracycline containing chemotherapy in high risk breast cancer patients. (2009) (11)
Prognostic significance of residual cancer tissue after diagnostic biopsy in breast carcinoma. Three-year short-term results. (1984) (10)
Clinical features of malignant haemangiopericytomas and haemangioendotheliosarcomas. (1988) (10)
Immunoglobulin (IgG and IgM) metabolism in patients with rheumatoid arthritis. (1973) (10)
Weekly oral idarubicin in postmenopausal women with advanced breast cancer. A phase II study. (1990) (10)
Lack of TIMP-1 tumor cell immunoreactivity predicts effect of adjuvant anthracycline based chemotherapy in patients (n=647) with primary breast cancer. (2009) (10)
Endocrine Treatment of Advanced Breast Cancer (1986) (10)
Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG). (1993) (10)
Phase II study with taxotere(RP56976) in advanced soft tissue sarcomas of the adult (1993) (9)
Impact of axillary dissection on staging and regional control in breast tumors < or = 10 mm--the DBCG experience. The Danish Breast Cancer Cooperative Group (DBCG), Rigshisoutalet, Copenhagen, Denmark. (2000) (9)
Studies on the correlation between rate of biotransformation and haematological toxicity of cyclophosphamide. (2009) (9)
Adjuvant Chemotherapy in Premenopausal Patients: A More Complicated Form of Oophorectomy? (1987) (9)
Molecular cytogenetic analysis of a nontumorigenic human breast epithelial cell line that eventually turns tumorigenic: Validation of an analytical approach combining karyotyping, comparative genomic hybridization, chromosome painting, and single‐locus fluorescence in situ hybridization (1997) (9)
Polysomy of Chromosome 17 in Breast Cancer. (2009) (9)
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98 (2017) (8)
Treatment of advanced soft tissue sarcomas with low-dose methotrexate: a phase II trial by the European Organization of Research on Treatment for Cancer (EORTC) Soft Tissue and Bone Sarcoma Group. (1984) (8)
The extravascular retention of albumin in wound tissue and its contribution to the postoperative hypoalbuminaemia in rabbits. (1969) (8)
Pharmacokinetics of Medroxyprogesterone Acetate Administered by Oral and Intramuscular Route (1981) (8)
N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group. (1982) (8)
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1–98 (2007) (8)
Castration induced by cytotoxic chemotherapy. (1989) (8)
Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study. (1984) (8)
Letrozole in the treatment of breast cancer (2005) (8)
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study (2004) (8)
Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group. (2003) (7)
Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue. (2003) (7)
Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. Breast Cancer Cooperative Group. (1986) (7)
Significance of incisional biopsy in breast carcinoma: results from a clinical trial with intended excisional biopsy. (1989) (7)
The diagnosis of liver metastases by ultrasonic and radioisotope scanning. (1978) (7)
The Turnover in Humans of Polymerized Human Serum Albumin and of Fractions of Human Serum Albumin with Different N–F Transformation Patterns (1969) (7)
Adjusting for Selective Crossover in Analyses of Letrozole (Let) Versus Tamoxifen (Tam) in the BIG 1-98 Trial. (2009) (7)
Treatment of advanced breast cancer with progestins. (1981) (7)
DBCG trial 89B comparing adjuvant CMF and ovarian ablation: Similar outcome for eligible but non-enrolled and randomized breast cancer patients (2008) (7)
674 Topoisomerase II alpha (TOP2A) alterations as a predictive marker for epirubicin sensitivity in 805 high-risk breast cancer patients. A randomised DBCG trial (DBCG89D) (2003) (7)
Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group. (1981) (7)
An overview of the EORTC Breast Cancer Cooperative Group's activities. (1983) (6)
Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. A study of the EORTC Soft Tissue and Bone Sarcoma Group. (1989) (6)
Site-specific effect of chemotherapy in patients with breast cancer. (1992) (6)
Variations in prognostic factors in primary breast cancer throughout the menstrual cycle. (2000) (6)
Advanced breast cancer--new approaches to treatment: workshop report. (1988) (6)
Treatment of advanced breast cancer with tamoxifen: Evaluation of the dose-response relationship at two dose levels (1982) (6)
[Mammographic screening in the municipality of Copenhagen. Results of the first screening round]. (1996) (6)
KAPOSI'S SARCOMA IN HOMOSEXUAL MEN: IS IT A NEW DISEASE (1982) (6)
[Adjuvant chemotherapy in premenopausal and menopausal high-risk patients with breast cancer. 4. Results of the DBCG (Danish Breast Cancer Cooperative Group) 77B study]. (1991) (6)
Treatment costs of adjuvant cytotoxic therapy in premenopausal breast cancer patients. (1988) (6)
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group. (1992) (6)
Improved progression-free survival from the addition of vinorelbine to epirubicin in first line chemotherapy of metastatic breast cancer (2001) (6)
Randomized phase II study of neoadjuvant chemotherapy in soft tissue sarcomas in adults. Protocol 62874 (1993) (6)
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients (2004) (6)
[Mammographic examinations in Denmark, 1990-1991]. (1994) (6)
Danish Breast Cancer Cooperative Group (DBCG). Present status and experience. (1984) (6)
Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer (2010) (6)
The place of chemotherapy in the management of soft tissue sarcoma: experiences of the EORTC Soft Tissue and Bone Sarcoma Group. (1989) (6)
[Mammography screening in the county of Copenhagen. Results of the first three screening rounds]. (2002) (6)
Exemestane following tamoxifen in postmenopausal women with primary breast cancer. (2004) (6)
How to improve cytotoxic therapy in advanced breast cancer. (1990) (5)
Equity and improvement in outcome of breast cancer in Denmark. (1994) (5)
A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients (2004) (5)
Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life-table analysis and steroid hormone receptor status (1985) (5)
Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer. (1986) (5)
[Insulin Monotard and Insulin Lente. Comparison of absorption and clinical effects]. (1975) (5)
Clinical Infrastructures to Support Proteomic Studies of Tissue and Fluids in Breast Cancer* (2004) (5)
[Improved prognosis of breast cancer]. (1994) (5)
Review of the clinical trials activity of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of Cancer. (1988) (5)
Aromatase inhibitors (AI) for elderly patients: Efficacy, compliance and safety according to patient age in the BIG 1–98 trial (2007) (5)
Oral idarubicin in the treatment of advanced breast cancer. (1989) (4)
Anthracycline extravasation in breast cancer patients. Effective treatment with dexrazoxane* in three multicenter trials (2008) (4)
Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. (2012) (4)
Histopathological grade and response to chemotherapy in advanced soft tissue sarcomas. (1993) (4)
BIG 1-98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. (2006) (4)
One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. (2013) (4)
Vimentin expression in 98 breast cancers with medullary features and its prognostic significance (2005) (4)
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients (2020) (4)
Principles and indications of endocrine treatment of advanced breast cancer. (1980) (4)
Gastric and pancreatic function and the absorption of iron, vitamin B12, and calcium after proximal gastric resection for cancer in the upper part of the stomach. (1969) (4)
[Should all younger patients with breast cancer be offered adjuvant cytotoxic chemotherapy?]. (2000) (4)
Chemotherapy in Advanced Soft Tissue Sarcoma — The EORTC Experience (1988) (4)
Is DBCG abreast of new developments? (2018) (4)
The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study (2018) (3)
Do changes in lymph node status distribution explain trends in survival of breast cancer patients in Denmark? (2006) (3)
Anthracyclines in the Treatment of Early Breast Cancer (2012) (3)
Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial (2018) (3)
Clinical Impact of Introduction of Mammography Screening in a Non-Screening Country (2002) (3)
Detection of metabolic denaturation of serum albumin by gel electrophoresis. (1973) (3)
Combination chemotherapy with CCNU, melphalan, methotrexate, and prednisone (CAMP) in 35 patients with advanced breast cancer. (1977) (3)
The role of anthracyclines in adjuvant chemotherapy of breast cancer: a critical appraisal. (1996) (3)
65. Fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen (1995) (3)
Clinical trial of rubidazone in solid tumors and malignant lymphomas. (1978) (3)
Endocrine Aspects in Adjuvant Therapy for Early Breast Cancer (1986) (3)
Discussion at the Satellite symposium: Ifosfamide in gynecological tumors (2004) (3)
The pharmacokinetics of cyclophosphamide in man following treatment with methotrexate. (2009) (3)
Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxieen (2006) (3)
[Sarcoma treatment in Denmark]. (1990) (3)
[Treatment of primary breast cancer. Consequences of mammographic screening in the municipality of Copenhagen]. (1996) (3)
Adjuvant systemic therapy in breast cancer. (1993) (3)
Ifosfamide plus Adriamycin in Advanced Soft Tissue Sarcomas (1987) (3)
Rationale and use of epirubicin-based therapy in the adjuvant setting. (2000) (2)
Provision of data from the clinical database and of biological material from the tumor bank of the Danish Breast Cancer Cooperative Group 2008–2017 (2018) (2)
Currently active protocols in the EORTC Breast Cancer Cooperative Group. (1984) (2)
New endocrine agents in the treatment of breast cancer. (1995) (2)
A randomized trial comparing the effect of epirubicin and doxorubicin in soft tissue sarcoma (1987) (2)
Metabolic and gel-electrophoretic properties of albumin isolated from wound tissue. (1968) (2)
Adjuvant hormonal therapy: whom to treat. (1989) (2)
[Mammographic screening in the county of Copenhagen. Clinical consequences of the first three screening rounds]. (2002) (2)
The transcapillary passage of different proteins in the operative wound (1969) (2)
Prediction of responsiveness to adjuvant anthracyclines in high-risk breast cancer patients. (2016) (2)
Soft tissue sarcomas in adults. Surgical, radiologic and cytotoxic treatment. (1984) (2)
[Adjuvant endocrine treatment of postmenopausal patients with breast cancer with high risk of recurrence. 5. Results from the DBCG (Danish Breast Cancer Cooperative Group) 77C randomized trial]. (1991) (2)
The application of whole-body counting to studies of the turnover of 131I-labelled plasma proteins. (1969) (2)
Pregnancy before and after breast cancer (2003) (2)
The value of routine biochemical and surgical pathology quantities in predicting recurrence in high-risk patients following surgery for primary breast cancer. (1983) (2)
[The significance of reproductive history for prognosis of primary breast cancer]. (2001) (2)
Conclusions and Guidelines (1995) (2)
Concurrent tamoxifen (TAM) + cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM + delayed CEF after six months of endocrine therapy in metastatic breast cancer--a randomized trial from the Danish Breast Cancer Cooperative Group (DBCG). (1996) (2)
Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group. (1992) (2)
[Prognosis after surgical treatment of breast cancer. 3. The low-risk group of the DBCG (Danish Breast Cancer Cooperative Group)]. (1991) (1)
A phase III study of prednimustine (LEO 1031) in advanced breast cancer. A preliminary report. (1980) (1)
Phase II study with liposomal muramyl tripeptide phophatidylethanolamine (MTP/PE) in soft tissue sarcomas (STS) (1993) (1)
S37 Characteristics of breast cancer patients unlikely to benefit from adjuvant therapy (2011) (1)
3rd EORTC Breast Cancer Working Conference, Amsterdam, 27–29 April 1983 (1983) (1)
Introduction: Setting New Standards in Aromatase Inhibitor Therapy (2003) (1)
[Medical treatment of cancer--an elucidating report]. (1988) (1)
The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs. (2010) (1)
Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study. (1982) (1)
Second-line chemotherapy with tauromustine in metastatic breast cancer in postmenopausal women: a phase II study. (1987) (1)
[Significance for prognosis of delayed diagnosis and treatment of breast cancer]. (1995) (1)
The extravascular retention of serum albumin in the operative wound. (1968) (1)
[Mammographic screening in the municipality of Copenhagen 1991-1997. Evaluation of the preoperative assessment]. (2002) (1)
Phase II study of ifosfamide + adriamycin in advanced soft tissue sarcoma in adults. A preliminary analysis. (1986) (1)
Inappropriate ATAC on tamoxifen. (2008) (1)
Advanced breast cancer. New approaches to treatment (1988) (1)
Prednimustine in advanced breast cancer: a review. (1986) (1)
Adjuvant chemotherapy and subsequent malignant disease (1991) (1)
Adjuvant CMF +/− tamoxifen (TAM) in premenopausal high-risk patients (PHRPs) with early breast cancer (1998) (1)
Toxicity and effect of single agent vinorelbine (V) in anthracycline-resistant metastatic breast cancer (ARMBC). Preliminary results of a phase I–II study by the danish breast cancer cooperative group (DBCG) (1997) (1)
CHEMOTHERAPY AND SURVIVAL IN BREAST CANCER (1980) (1)
[Treatment of drug-resistant metastasizing cancer of the breast with an antiestrogen]. (1978) (1)
Aromatase inhibitors in the early adjuvant setting – the latest evidence (2006) (1)
[Medical treatment of cancer]. (1997) (1)
TIMP-1 and responsiveness of estrogen receptor negative breast cancer to preoperative epirubicin and cyclophosphamide with or without gefitinib (2009) (1)
[Breast cancer]. (2002) (1)
A randomized phase III trial of adjuvant endocrine therapy with tamoxifen for one year (TAM1) vs tamoxifen for two years (TAM2) in postmenopausal high risk patients with estrogen receptor positive or estrogen receptor unknown breast cancer. A DBCG study (1998) (1)
The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer (2004) (1)
849 Preliminary report of a randomized phase II study comparing two different ifosfamide (IF) regimens in advanced soft tissue sarcoma patients (PTS) failing first-line anthracyclines (1995) (1)
Letter: Cyclophosphamide activation and corticosteroids. (1974) (1)
Clinical trials (1994) (1)
569 Treatment of advanced breast cancer with medroxyprogesterone acetate: A randomized evaluation of the dose-response relationship at two-dose levels. A phase III trial (1983) (1)
Phase II study of ifosfamide + adriamycin in advanced soft tissue sarcoma in adults (2004) (1)
Validation of the predictive value of tissue inhibitor of metalloproteinases-1 for the response to first-line chemotherapy in metastatic breast cancer. (2009) (1)
Prognostic Factors in Node-Negative Breast Cancer Patients (1990) (1)
Values and Limitations of Current Criteria for Objective Response in Advanced Breast Cancer (1987) (1)
582 CMF versus CMF + tamoxifen in advanced breast cancer. Final analysis of a randomized eortc study (1983) (1)
21 Histologic type of local recurrence and prognostic significance in breast conservation vs. mastectomy in invasive breast cancer: A 20-year update of a randomized trial (2003) (1)
[Adjuvant treatment of breast cancer. Endocrine therapy]. (2007) (1)
[Abdominal trauma. Review of 142 nonpenetrating abdominal injuries during a 12-year period]. (1969) (0)
Risk of late stage breast cancer following a childbirth (1999) (0)
PrimaryTumor Levels ofTissue Inhibitor of Metalloproteinases-1 Are Predictive of Resistance to Chemotherapy in Patients with Metastatic Breast Cancer (2006) (0)
Is breast conserving surgery a risk factor in young breast cancer patients (2001) (0)
Moderate-Dose Adjuvant Chemotherapy Temporarily Impairs Oral Health-Related Quality of Life (2011) (0)
[We should have a standard basic attitude to patients]. (1977) (0)
[Editorial: Breast neoplasms]. (1975) (0)
Medullarary carcinoma of the breast, prognostic importance of characteristic features evaluated in a multivariate cox analysis (1993) (0)
Endocrine Treatment of Malignant Disease (1993) (0)
Epirubicin is not a substitute for Doxorubicine in advanced soft tissue sarcomas. Final data from the EORTC Soft Tissue and Bone Sarcoma Group (1998) (0)
Abstracts of Papers Presented at the Connective Tissue Oncology Society 4th Annual Scientific Meeting, 12–14 November 1998, Vancouver, BC, Canada (1999) (0)
A randomized phase II study comparing aminoglutethimide vs. trilostane vs. MPA vs. hydrocortisone: An E.O.R.T.C. study (1986) (0)
[Mammography screening--ideology contra science]. (2006) (0)
Abstract P4-07-04: Preoperative Plasma Concentration of MMP-9/TIMP-1 Complexes Is Not Associated with Disease Outcome in Primary Breast Cancer (N=483) (2010) (0)
312 The prognostic and predictive value of estrogen and progesterone receptor determinations in primary breast cancer (1983) (0)
[Endocrine treatment of metastasizing breast cancer in menopausal women. A randomized comparison between tamoxifen (Nolvadex) versus tamoxifen and medroxyprogesterone acetate (Clinovir)]. (1979) (0)
Reproducibility of bone scintigraphy with /sup 99m/Tc polyphosphate (1975) (0)
Editorial (2010) (0)
Chemotherapy and survival in breast cancer. (1980) (0)
[Tamoxifen (Nolvadex): therapeutic effect in metastasizing breast cancer]. (1979) (0)
Letrozole versus Tamoxifen as First-Line Treatment for Metastatic Breast Cancer (2003) (0)
353 Safety of letrozole and tamoxifen monotherapy: updated BIG 1-98 (2010) (0)
Pregnancy after breast cancer (1998) (0)
The role of endocrine therapy in this setting (2002) (0)
[Cytostatic combination therapy in metastatic breast cancer]. (1973) (0)
Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: A phase I–II study (2005) (0)
47. A randomized trial of concurrent tamoxifen (TAM) and cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM and delayed CEF after 6 months of endocrine therapy in metastatic breast cancer (1995) (0)
Compositions and methods for predicting the outcome of a treatment (2006) (0)
[Cytostatic treatment of metastasizing breast cancer. A prospective controlled comparison between single drug and multiple drug chemotherapy]. (1977) (0)
[Posterior abdominal aortic aneurysm. A report on 3 autopsy cases]. (1966) (0)
Prednimustine in advanced malignant melanoma: a phase II study. (1987) (0)
Rate of Synthesis of Albumin during the Early Postoperative Period (1972) (0)
[Control of the myocardial pump function during cytostatic treatment with anthracycline]. (1996) (0)
[Reduced capacity for cutaneous inflammatory reaction in patients with neoplastic diseases]. (1974) (0)
Preferred papers sessionPP-6-20 Survival Following First Episode of Hypercalcaemia in Breast Cancer Patients (1996) (0)
New options for the therapy of advanced breast cancer (2017) (0)
[Menstrual cycle and surgery of breast cancer. Point of time for the surgery of primary breast cancer in connection with menstrual cycle is without prognostic significance]. (1995) (0)
[Rationalization profits of radiographic diagnosis with systematic follow-up DBCG (Danish Breast Cancer Cooperative Group) programs. 1]. (1991) (0)
386 High-dose chemotherapy with stem cell support in high-risk primary breast cancer. An analysis of the effect on overall survival the Danish experience from a comparison study (2003) (0)
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone. (1977) (0)
WITHDRAWN: Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group. (2008) (0)
Correspondence re: V. C. Jordan and V. J. Assikis, Endometrial Carcinoma and Tamoxifen: Clearing Up a Controversy. Ciin. Cancer Res., 1: 467-472, 1995. (1996) (0)
650 Medullary carcinoma of the breast, histopathological and clinical characteristics (1995) (0)
0-78. Axillary dissection of level I and II - also when tumours are small? The DBCG recommendation (1997) (0)
Intermittent/alternated therapy with tamoxifen and medroxy-progesterone acetate prolongs time to resistance to tamoxifen without benefit for (progression free) survival in patients with advanced breast cancer. Results of an EORTC phase III study (trial 10863) (2004) (0)
Adjuvant systemic therapy in primary breast cancer. (1984) (0)
Advanced Breast Cancer (2002) (0)
Critical review of adjuvant therapy in premenopausal patients. (1989) (0)
5.2. Required analytical quality in clinical chemical time series that arise during breast cancer follow-up (1980) (0)
[Should chemotherapy or endocrine therapy be used as first choice in patients with advanced breast cancer? A status article based on the Cochrane analysis "Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer"]. (2004) (0)
402 Adjuvant endocrine therapy in pre- and postmenopausal women with primary breast cancer. A 25-year report of the Copenhagen breast cancer trials (2003) (0)
Survival patterns according to age and treatment among breast cancer patients (1998) (0)
Endocrine therapy in locally recurrent and metastatic breast cancer (2003) (0)
How to improve adjuvant treatment results in postmenopausal patients. (1989) (0)
[Mammography screening--one more time]. (2005) (0)
CCNU, melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in the treatment of advanced breast cancer in postmenopausal women. (1980) (0)
Heavy international support to the Danish mammography screening programme (2017) (0)
Endocrine treatment in advanced breast cancer (1997) (0)
PP-6-1 Time since birth is a prognostic factor in primary breast cancer (1996) (0)
PredictingRecurrencein Patientswith BreastCancer from Cumulative LaboratoryResults:A New Techniquefor the Applicationof Time Series Analysis (1982) (0)
Fluids in Breast Cancer. (2004) (0)
[Adjuvant systemic treatment of primary breast cancer]. (1994) (0)
Comments on Economic Evaluation of Chemotherapy (1997) (0)
Endocrine Therapy In Primary and Advanced Breast Cancer (1986) (0)
S42 Scandinavian/nordic adjuvant trials in breast cancer (1998) (0)
Nordic trials of adjuvant therapy in primary breast cancer. (1998) (0)
Editorial (2007) (0)
Treatment of anthracycline extravasation with dexrazoxane: Pharmacokinetics and update on efficacy and safety from three multicenter trials (2016) (0)
[The reproducibility of bone scintigraphy with 99mTechnetium polyphosphate]. (1975) (0)
Phase 11-study of ifosfamide (IFS) + adriamycin (ADM) in advanced soft tissue sarcoma in adults — A preliminary analysis (1986) (0)
[Abdominal aortic aneurysm. A survey with special reference to the posterior aneurysm]. (1966) (0)
Tamoxifen and castration in addition to cytotoxics in the treatment of premenopausal patients with metastatic breast cancer : A phase III trial of CAF + castration vs CAF + castration + Tamoxifen (1992) (0)
Turnover of transferrin and gamma-G-globulin after a simple mastectomy. (1970) (0)
CONTINUOUS CYCLOPHOSPHAMIDE TREATMENT AND ADRENAL FUNCTION (1976) (0)
375 Antiandrogen and antiestrogen in the treatment of advanced malignant melanoma (1983) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Henning T. Mouridsen?

Henning T. Mouridsen is affiliated with the following schools:

Henning T. Mouridsen's Academic­Influence.com Rankings

Henning T. Mouridsen's Degrees

Why Is Henning T. Mouridsen Influential?

Henning T. Mouridsen's Published Works

Published Works

What Schools Are Affiliated With Henning T. Mouridsen?

Henning T. Mouridsen's AcademicInfluence.com Rankings